View details of this raise on Seedstage

Redmond, OR

Developing a minimally invasive treatment to prevent wisdom teeth formation in children.

• Innovative Dental Treatment: TriAgenics has created a procedure to prevent wisdom teeth from forming, eliminating the need for extraction.
• Target Age Group: The Zero3 TBA procedure is designed for children aged 6-12, targeting tooth buds before they develop into wisdom teeth.
• FDA Clearance: The company is seeking FDA clearance to ensure the safety and effectiveness of its medical device.
• Global Expansion Plans: Following U.S. launch, TriAgenics plans to expand internationally, with patents secured in multiple countries.
• Broad Patent Portfolio: TriAgenics holds 37 issued patents, supporting its innovative approach to dental care.

TriAgenics has developed a minimally invasive dental treatment aimed at preventing the formation of wisdom teeth in children. This innovative procedure, known as Zero3 TBA, targets tooth buds in children aged 6-12, eliminating the need for traditional wisdom teeth extraction. The treatment is designed to be quick, taking about a minute per tooth bud, and does not require cutting or stitches, allowing children to resume normal activities immediately. The company is currently seeking FDA clearance to bring this technology to market, with plans for a commercial launch in the U.S. followed by global expansion.

The Zero3 TBA procedure offers a new standard of care for dentists, enabling them to provide preventive treatment in-house rather than referring patients to oral surgeons. This approach not only benefits patients by reducing the risks and recovery time associated with traditional extractions but also provides dentists with a new revenue stream. TriAgenics holds a broad patent portfolio and aims to replicate the success of companies like Align Technology by transforming the wisdom tooth extraction market. The company is focused on meeting regulatory requirements and conducting clinical trials to ensure the safety and effectiveness of its device.

Company Info

TriAgenics offers a minimally invasive treatment to prevent wisdom teeth formation, aiming to replace traditional extraction methods.

TriAgenics has developed a minimally invasive dental treatment aimed at preventing the formation of wisdom teeth in children. The procedure, known as Zero3 TBA, targets tooth buds in children aged 6-12, eliminating the need for traditional wisdom teeth removal surgeries. This innovative approach allows general dentists to perform the procedure quickly and painlessly, without the need for cutting or stitches, enabling children to resume normal activities immediately.

The company plans to market its Zero3 surgical kits to dentists, offering a new revenue stream while reducing the need for referrals to oral surgeons. With a focus on safety and precision, TriAgenics aims to establish Zero3 TBA as the new standard of care in dental practices, similar to how Invisalign transformed orthodontics. The company holds a broad patent portfolio and is currently seeking FDA clearance to bring its product to market.